Asymptomatic hyperuricaemia (HU) is considered a pathogenic factor in multiple disease
contexts, but a causative role is only proven for the crystalline form of uric acid in gouty …

Hyperuricemia, ie increased serum uric acid (UA) concentration, is a common problem in
clinical practice. While there are clear guidelines concerning management of symptomatic …

Gout and hyperuricemia are present in 25% and 60% of patients with chronic kidney
disease (CKD), respectively. Despite the common association, the role of uric acid in the …

The relationship between hyperuricemia, gout, and renal disease has been investigated for
several years. From the beginning, kidney disease has been considered a complication of …

Asymptomatic hyperuricaemia affects~ 20% of the general population in the USA, with
variable rates in other countries. Historically, asymptomatic hyperuricaemia was considered …

Hyperuricemia (elevated serum uric acid) is prevalent, and an important mediator of gout, an
increasingly common condition. In addition, hyperuricemia is associated with metabolic …

Recently, research has redirected its interests in uric acid (UA) from gout, an inflammatory
disease in joints, to groups of closely interrelated pathologies associated with …

Uric acid is a product of purine metabolism and has been linked to gout and kidney calculi.
Chronic kidney disease (CKD) and hypertension (HTN) are two major public health …

Metabolic end products accumulate in kidney failure, including uric acid (UA), a terminal
product of purine catabolism. Hyperuricemia (HUA) can cause gout and has been …

In gouty patients, urate lowering therapies (ULTs) are recommended to bring serum uric acid
(SUA) levels below 6.0 mg/dL, with the aim of dissolving urate depositions, thereby reducing …